Norgestrel (DL-Norgestrel)

Subscribe to Selected New Research on Norgestrel

86 relevant articles (3 outcomes, 8 trials/studies) found for this Drug

Description: A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis.

Also Known As:

DL-Norgestrel; Ovrette; Neogest; Postinor; Schering Brand of Norgestrel; Wy-3707; Wyeth Brand of Norgestrel; DL Norgestrel; Norgestrel Schering Brand; Norgestrel Wyeth Brand; Wy 3707; Wy3707; 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-

Relationship Network

Drug Context: Research Results

Experts

1.	Susca, F: 1 article (01/2000)
2.	Fanelli, M: 1 article (01/2000)
3.	Bukvic, D: 1 article (01/2000)
4.	Bukvic, N: 1 article (01/2000)
5.	Guanti, G: 1 article (01/2000)

Related Diseases

1.	Hemorrhage 05/01/2006 - "The percentage of women experiencing cyclic bleeding was greater with CEE/norgestrel, as was the mean duration and severity of bleeding" 10/01/1978 - "Both implant regimens were associated with a high frequency of reduced bleeding and norgestrel patients had also a high proportion of increased and irregular bleeding" 09/01/1975 - "50 and 100 mg norgestrel IVRs caused a lower incidence of bleeding and ovulation, but a previous study with similar rings containing medroxyprogesterone acetate (MPA) produced more favorable results" 02/01/1997 - "She was given hormone replacement with a conjugated equine oestrogen/norgestrel combination, resulting in regular withdrawal bleeding" 01/01/1992 - "On the other hand, Continuin and Postinor did not prove reliable; they had frequent side effects such as irregular bleeding and extrauterine pregnancy (6.4%)" Order ALL the reference details at left...
2.	Menorrhagia 02/01/1993 - "4 years later she gradually developed menorrhagia which improved upon changing the OC to .3 mg norgestrel and 30 mcg EE" 11/05/1979 - "Menstrual bleeding disorders were the most frequent reasons for discontinuing subcutaneous implant use and occurred more often among the levo-norgestrel patients (generally metrorrhagia and menorrhagia)" Order ALL the reference details at left...
3.	Hidradenitis Suppurativa 09/01/1986 - "In order to examine whether anti-androgen therapy was effective in hidradenitis suppurativa (HS), ethinyloestradiol 50 micrograms/cyproterone acetate 50 mg in a reverse sequential regimen was compared with ethinyloestradiol 50 micrograms/norgestrel 500 micrograms (Eugynon 50) in 24 female patients" Order ALL the reference details at left...
4.	Breast Neoplasms (Breast Cancer) 05/01/1993 - "These studies suggest that the 19-norprogestins norgestrel and gestodene stimulate MCF-7 breast cancer cell growth by activating the oestrogen receptor." 05/01/1993 - "Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism." 09/16/2005 - "The MWS, an observational study, showed an increased breast cancer risk in users of estrogens combined with either medroxyprogesterone acetate (MPA), norethisterone, or norgestrel" 07/01/2000 - "These compounds were tested on BT-474 human breast cancer cells at concentrations of 10(8)-10(-5) M, with estradiol (estrogen), norgestrel (progestin) and dihydrotestosterone (androgen) used as positive controls, and ethanol (solvent) as a negative control" 11/01/1995 - "In growth assays using the MCF-7 and T47D:A18 human breast cancer cell lines, we find that only estradiol, norgestrel and RU486 stimulate proliferation, and this effect can be blocked by the pure antiestrogen ICI 182780" Order ALL the reference details at left...
5.	Chromosome Aberrations (Chromosome Abnormalities) 03/01/2006 - "The effect of NDGA was studied against norgestrel induced genotoxic damage, using sister chromatid exchanges (SCEs), chromosomal aberrations (CAs), mitotic index (MI) and replication index (RI) as parameters" 01/01/2000 - "The present study was undertaken to evaluate through carefully planned and controlled investigations the in vitro cytogenetic effects of oral contraceptives (ethynilestradiol and norgestrel mixed in the proportion 1:5) using three different concentrations, with two different durations of treatment (48 and 72 h), on two types of human cells (lymphocytes and fibroblasts) and a series of short-term test procedures: sister chromatid exchange (SCE), micronucleus test (MN), and chromosome aberrations (CA)" 07/25/2001 - "norgestrel and norethindrone was carried out on human lymphocyte chromosomes using chromosomal aberrations (CA), sister chromatid exchanges (SCE) and cell growth kinetics as parameters" 01/01/2000 - "In conclusion, our data confirm that hormones do not induce structural chromosome aberrations in lymphocytes and indicate that ethynilestradiol and norgestrel have an aneugenic effect on fibroblast and lymphocyte cultures; FISH analysis on micronuclei from lymphocyte cultures and anaphase preparations from fibroblast cultures support this hypothesis" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ethinyl Estradiol (Estinyl)
2.	Estradiol (Estrace)
3.	Ethinyl Estradiol-Norgestrel Combination (Ovral)
4.	Dydrogesterone
5.	Cyproterone Acetate
6.	Medroxyprogesterone 17-Acetate (Depo-Provera)
7.	Norethindrone (Norethisterone)
8.	Estrogens (Estrogen)
9.	Levonorgestrel (Plan B)
10.	Oral Contraceptives

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Contraception (Birth Control)
3.	Intrauterine Devices (Intrauterine Device)
4.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
5.	Cesarean Section (Caesarean Section)

Best Treatments:
Research Summary Report
on Hemorrhage

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2879 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>